Literature DB >> 30532879

Mid-ventricular obstruction occurred in hypertrophic left ventricle of heterozygous Fabry's disease-Favorable effects of cibenzoline: A case report.

Shinya Nishizawa1, Tomoko Osamura1, Norikazu Takechi1, Shigehiro Kusuoka1, Keizo Furukawa1.   

Abstract

A 54-year-old woman visited our hospital because of palpitation and dizziness. Systolic ejection murmur, Levine IV/VI, was heard at the left sternal border and atrial gallop was auscultated at apex. Echocardiogram demonstrated diffuse hypertrophy of the left ventricular walls extending to the apex. The left ventricular walls increased symmetrically; the septal and the posterior wall measured approximately 26 mm and 30 mm in thickness, respectively. Apical two-chamber views revealed a narrow outflow of the left ventricular cavity at apex with a distinct convergence zone, where color flow Doppler imaging showed turbulent jet flow from mid to late systole. The leukocyte α-galactosidase A activity was lower than normal. Percutaneous endomyocardial biopsy showed specific change for Fabry's disease by electron microscopy. On cardiac catheterization, mid-ventricular resting pressure gradient of approximately 90 mmHg was shown. This pressure gradient dramatically disappeared after intravenous administration of 70 mg of cibenzoline. We describe a rare case of Fabry's disease that revealed diffuse hypertrophy having dynamic obstruction at mid-left ventricle, like mid-ventricular obstruction, and the administration of cibenzoline had beneficial effects on pressure gradient of mid-left ventricle.

Entities:  

Keywords:  Cibenzoline; Fabry's disease; Mid-ventricular obstruction

Year:  2011        PMID: 30532879      PMCID: PMC6265431          DOI: 10.1016/j.jccase.2011.07.007

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN: 1878-5409


  13 in total

1.  Class Ia antiarrhythmic drug cibenzoline: a new approach to the medical treatment of hypertrophic obstructive cardiomyopathy.

Authors:  M Hamada; Y Shigematsu; S Ikeda; Y Hara; H Okayama; K Kodama; T Ochi; K Hiwada
Journal:  Circulation       Date:  1997-09-02       Impact factor: 29.690

2.  Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

Authors:  C M Eng; N Guffon; W R Wilcox; D P Germain; P Lee; S Waldek; L Caplan; G E Linthorst; R J Desnick
Journal:  N Engl J Med       Date:  2001-07-05       Impact factor: 91.245

3.  Onset and progression of the Anderson-Fabry disease related cardiomyopathy.

Authors:  Christoph Kampmann; Ales Linhart; Frank Baehner; Tomas Palecek; Christiane M Wiethoff; Elke Miebach; Catharina Whybra; Andreas Gal; Jan Bultas; Michael Beck
Journal:  Int J Cardiol       Date:  2008-06-24       Impact factor: 4.164

4.  Antiarrhythmic drug cibenzoline attenuates left ventricular pressure gradient and improves transmitral Doppler flow pattern in patients with hypertrophic obstructive cardiomyopathy caused by midventricular obstruction.

Authors:  Mareomi Hamada; Yuji Shigematsu; Shinji Inaba; Jun Aono; Shuntaro Ikeda; Kouki Watanabe; Akiyoshi Ogimoto; Tomoaki Ohtsuka; Yuji Hara; Jitsuo Higaki
Journal:  Circ J       Date:  2005-08       Impact factor: 2.993

5.  Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency.

Authors:  R O Brady; A E Gal; R M Bradley; E Martensson; A L Warshaw; L Laster
Journal:  N Engl J Med       Date:  1967-05-25       Impact factor: 91.245

6.  Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

Authors:  R Schiffmann; J B Kopp; H A Austin; S Sabnis; D F Moore; T Weibel; J E Balow; R O Brady
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

7.  An atypical variant of Fabry's disease in men with left ventricular hypertrophy.

Authors:  S Nakao; T Takenaka; M Maeda; C Kodama; A Tanaka; M Tahara; A Yoshida; M Kuriyama; H Hayashibe; H Sakuraba
Journal:  N Engl J Med       Date:  1995-08-03       Impact factor: 91.245

8.  Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey.

Authors:  Ales Linhart; Christoph Kampmann; José L Zamorano; Gere Sunder-Plassmann; Michael Beck; Atul Mehta; Perry M Elliott
Journal:  Eur Heart J       Date:  2007-05-05       Impact factor: 29.983

9.  Inhibition of the myocardial Ca2+ inward current by the class 1 antiarrhythmic agent, cibenzoline.

Authors:  M Holck; W Osterrieder
Journal:  Br J Pharmacol       Date:  1986-04       Impact factor: 8.739

10.  Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.

Authors:  Frank Weidemann; Markus Niemann; Frank Breunig; Sebastian Herrmann; Meinrad Beer; Stefan Störk; Wolfram Voelker; Georg Ertl; Christoph Wanner; Jörg Strotmann
Journal:  Circulation       Date:  2009-01-19       Impact factor: 29.690

View more
  1 in total

1.  Evidence of evolution towards left midventricular obstruction in severe Anderson-Fabry cardiomyopathy.

Authors:  Francesca Graziani; Rosa Lillo; Elena Panaioli; Gionata Spagnoletti; Maurizio Pieroni; Paolo Ferrazzi; Antonia Camporeale; Elena Verrecchia; Ludovico Luca Sicignano; Raffaele Manna; Filippo Crea
Journal:  ESC Heart Fail       Date:  2020-11-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.